Myelodysplastic syndromes
L Adès, R Itzykson, P Fenaux - The Lancet, 2014 - thelancet.com
Myelodysplastic syndromes are clonal marrow stem-cell disorders, characterised by
ineffective haemopoiesis leading to blood cytopenias, and by progression to acute myeloid …
ineffective haemopoiesis leading to blood cytopenias, and by progression to acute myeloid …
Targeting DNA methylation for epigenetic therapy
Patterns of DNA methylation are established during embryonic development and faithfully
copied through somatic cell divisions. Based on current understanding of DNA methylation …
copied through somatic cell divisions. Based on current understanding of DNA methylation …
How we manage adults with myelodysplastic syndrome
P Fenaux, U Platzbecker, L Ades - British journal of …, 2020 - Wiley Online Library
The prognosis in Myelodysplastic syndromes (MDS), although recently refined by molecular
studies, remains largely based on conventional prognostic scores [International Prognostic …
studies, remains largely based on conventional prognostic scores [International Prognostic …
[HTML][HTML] Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes
N Gattermann, C Finelli, M Della Porta, P Fenaux… - …, 2012 - ncbi.nlm.nih.gov
Background Reductions in transfusion requirements/improvements in hematologic
parameters have been associated with iron chelation therapy in transfusion-dependent …
parameters have been associated with iron chelation therapy in transfusion-dependent …
Epigenetic drug discovery: targeting DNA methyltransferases
JM Foulks, KM Parnell, RN Nix… - Journal of …, 2012 - journals.sagepub.com
Epigenetic modification of DNA leads to changes in gene expression. DNA
methyltransferases (DNMTs) comprise a family of nuclear enzymes that catalyze the …
methyltransferases (DNMTs) comprise a family of nuclear enzymes that catalyze the …
Prediction of synergistic anti-cancer drug combinations based on drug target network and drug induced gene expression profiles
Objective Synergistic drug combinations are promising therapies for cancer treatment.
However, effective prediction of synergistic drug combinations is quite challenging as …
However, effective prediction of synergistic drug combinations is quite challenging as …
Activity of azacitidine in chronic myelomonocytic leukemia
R Costa, H Abdulhaq, B Haq, RK Shadduck, J Latsko… - Cancer, 2011 - Wiley Online Library
BACKGROUND: Hypomethylating drugs are useful in the management of myelodysplastic
syndrome (MDS). Two of these drugs, azacitidine and decitabine, have received FDA …
syndrome (MDS). Two of these drugs, azacitidine and decitabine, have received FDA …
Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines
V Santini, PE Alessandrino, E Angelucci, G Barosi… - Leukemia research, 2010 - Elsevier
Since 2002, date of publication of the previous Italian Society of Haematology (SIE) practice
guidelines for management of myelodysplastic syndromes (MDS), novel disease-modifying …
guidelines for management of myelodysplastic syndromes (MDS), novel disease-modifying …
DNA hypermethylation as a chemotherapy target
Epigenetics refers to partially reversible, somatically inheritable, but DNA sequence-
independent traits that modulate gene expression, chromatin structure, and cell functions …
independent traits that modulate gene expression, chromatin structure, and cell functions …
Role of VEGF/VEGFR in the pathogenesis of leukemias and as treatment targets
G Song, Y Li, G Jiang - Oncology reports, 2012 - spandidos-publications.com
Angiogenesis plays an important role in solid tumor growth, progression and metastasis.
Evidence suggests that the progression of hematolymphoid malignancies also depends on …
Evidence suggests that the progression of hematolymphoid malignancies also depends on …